Status:

COMPLETED

Tolerability and Pharmacokinetics of Lacidipine With and Without the Co-administration of Telmisartan in Female and Male Healthy Subjects

Lead Sponsor:

Boehringer Ingelheim

Conditions:

Healthy

Eligibility:

All Genders

18-50 years

Phase:

PHASE1

Brief Summary

The objectives of this study are to compare the steady state pharmacokinetics of lacidipine with and without the co-administration of telmisartan and to compare the steady state pharmacokinetics of te...

Eligibility Criteria

Inclusion

  • Healthy male and female Caucasian subjects as determined by results of screening
  • Written informed consent in accordance with Good Clinical Practice and local legislation given
  • Age \>= 18 and \<= 50 years
  • Broca \>= -20% and \<= + 20%

Exclusion

  • Any finding of the medical examination (including blood pressure, pulse rate and Electrocardiogram (ECG) deviating from normal and of clinical relevance
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Surgery of gastrointestinal tract (except appendectomy)
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurologic disorders
  • History of orthostatic hypotension, fainting spells or blackouts
  • Chronic or relevant acute infections
  • History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
  • Intake of drugs with a long half-life (\> 24 hours) (\<= 1 month prior to administration or during the trial)
  • Use of any drugs which might influence the results of the trial (\<= 10 days prior to administration or during the trial)
  • Participation in another trial with an investigational drug (\<= 2 months prior to administration or during the trial)
  • Smoker (\> 10 cigarettes or \> 3 cigars or \> 3 pipes/day)
  • Inability to refrain from smoking on study days
  • Alcohol abuse (\> 60g/day)
  • Drug abuse
  • Blood donation \> 100 ml (\<= 4 weeks prior to administration or during the trial)
  • Any laboratory value outside the reference range of clinical relevance
  • Female only:
  • no reliable contraception (reliable are: oral contraceptives, 3-month injection, Intrauterine devices (IUD), sterilization)
  • Pregnancy or breast feeding period

Key Trial Info

Start Date :

October 1 1998

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

Estimated Enrollment :

26 Patients enrolled

Trial Details

Trial ID

NCT02203500

Start Date

October 1 1998

Last Update

August 6 2014

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.